IV CLINICAL UROLOGY MEETING THE PSA AND PROSTATE CANCER DILEMMA BILBAO February 23-24, 2017 Clínica IMQ Zorrotzaurre Organized by:
SOME REASONS TO ATTEND OUR MEETING The PSA test is not a prostate cancer marker and its elevation does not existence of a prostate cancer. Overdiagnosis means a diagnosis of prostate cancer without risk to the patient, i.e. a cancer that will not progress. The proportion of low-risk patients in both Europe and the USA is between 66% and 75%. Adequate diagnosis using markers and imaging decreases the number of low-risk cancers. Do indolent or low-risk tumors really exist? Will high resolution ultrasound replace the magnetic resonance in the Prostate Cancer diagnosis? What is the best option when we decide to make a focal treatment? These questions and more we hope to answer if you decide to come to Bilbao. A city worth visiting at any time of the year. Organizing Committee: Dr. Ander Astobieta Odriozola Dr. Mikel Gamarra Quintanilla Dr. Gaspar Ibarluzea González Dr. Jorge Mora Christian Dr. Guillermo Olaizola Fuertes Dr. José Gregorio Pereira Arias Dr. Andrea Sánchez Vázquez Dr. Felipe Urdaneta Salegui
BILBAO - February 23-24, 2017 February 23th, Thursday 14:00h. 15:00h. 15:30h.-15:40h. 15:40h.-16:00h. 16:00h.-16:15h. Welcome Cocktail. Registration. Welcome Remarks. Dr. Ander Astobieta, Dr. Nicolás Guerra Overdiagnosis and overtreatment in Prostate Cancer. Dr. Antonio Alcaraz How to avoid indolent and harmless Prostate Cancer. Dr. Ander Astobieta 16:15h. 16:15h.-16:30h. 16:30h.-16:45h. 16:45h.-17:00h. 17:00h.-17:15h. IMAGING IN PROSTATE CANCER DIAGNOSIS Moderators: Dr. Ander Astobieta, Dr. Pilar Laguna How can we identify men to biopsy: is magnetic resonance imaging the solution? Dr. Gonzalo Solís, Dr. Pedro Arguis Can clinically significant Prostate Cancer be detected with multiparametric magnetic resonance imaging? Dr. Harriet Thoeny Should prebiopsy multiparametric magnetic resonance imagen be offered to all biopsy-naive men undergoing prostate biopsy? Dr. Hashim U. Ahmed Multi-parametric Ultrasound. Dr. Pilar Laguna 17:15h. 17:15h.-17:30h. 17:30h.-17:45h. 17:45h.-18:00h. HIGH RESOLUTION ULTRASOUND. IS IT THE FUTURE? Moderators: Dr. Jean de la Rosette, Dr. Gaspar Ibarluzea High resolution 29 MHz micro-ultrasound. Dr. Sangeet Ghai Personal experience Dr. Jochen Walz Will Ultrasound replace MRI? Dr. Harriet Thoeny, Dr. Sangeet Ghai
THE PSA AND PROSTATE CANCER DILEMMA 18:00h. 18:00h.-18:30h. 18:30h.-18:45h. 18:45h.-19:00h. THE ROLE OF MOLECULAR MAKERS Moderators: Dr. Carlos Hernández, Dr. Mikel Gamarra Four-kallikrein panel predicts gigh-grade cancer on biopsy. Any other markers? What is the evidence? Dr. Anders Bjartell Detection of high-grade Prostate Cancer using a urinary markers. Dr. José Rubio Discussion. 19:00h.-19:30h. Pathology. Moderator: Dr. Carla Valenti Pons Histopathology assessment of Prostate Carcinoma in the needle biopsy. Dr. Ferrán Algaba 19:30h.-20:15h. 20:15h. Clinical cases. Moderators: Dr. José G. Pereira, Dr. Felipe Urdaneta Panelists: Dr. Anders Bjartell, Dr. José Rubio, Dr. Harriet Thoeny Afternoon closing remarks February 24th, Friday 08:30h.- 09:30h. Clinical case. Moderators: Dr. Miguel Sánchez Encinas, Dr. Andrea Sánchez Panelists: Dr. Alberto Briganti, Dr. Rafael Sánchez Salas, Dr. Pilar Laguna, Dr. Hashim U. Ahmed
BILBAO - February 23-24, 2017 09:30h.- 09:45h. Dismiss systematic transrectal ultrasound-guided and embrace targeted magnetic resonance imaging informed prostate biopsy: Is the paradigm ready to shift? Dr. Alberto Briganti 09:45h.-10:00h. Clinical utility of transperineal template-guided mapping biopsy of the prostate after negative magnetic resonance imaging guided transrectal biopsy. Dr. Xavier Cathelineau 10:00h.-10:15h. Template perineal biopsy vs. fusion biopsy vs. systematic biopsy. Dr. José María Banús 10:15h.-10:30h. Genetic disorders in prostate cancer. Dr. Antonio Alcaraz 10:30h.-10:45h. 10:45h.-11:30h. Discussion Coffee break 11:30h. 11:30h.-11:45h. 11:45h.-12:00h. 12:00h.-12:15h. 12:15h.-12:30h. FOCAL THERAPY Moderators: Dr. Carlos Llorente, Dr. Jorge Mora The challenge for urologists is to screen, detect, and treat prostate cancer Smarter : Will ablative technology result in smarter treatment? Dr. Pilar Laguna Focal Therapy: patients, interventions and outcomes Dr. Rafael Sánchez Salas The effects of focal therapy for prostate cancer on sexual function. Dr. Hashim U. Ahmed Salvage ablative therapy in prostate cancer. Dr. Jean de la Rosette
THE PSA AND PROSTATE CANCER DILEMMA 12:30h.-13:15h. Prostate patient selection for focal therapy Moderators: Dr. Rafael Sánchez-Salas, Dr. Asier Leibar Rationale for salvage. Dr. Jean de la Rosette Rationale for the high-risk patient. Dr. Hashim U. Ahmed 13:15h. 13:15h.-13:30h. 13:30h.-13:45h. 13:45h. -14:00h. 14:00h.-14:15h. 14:15h.-14:30h. MORE DILEMMAS IN PROSTATE CANCER TREATMENT Moderators: Dr. Antonio Alcaraz, Dr. José G. Pereira Surgycal anatomy of the prostate related to optimisation of cancer control and preservation of continence and erection in candidates for radical prostatectomy. Dr. Jochen Walz Optimal timing for early salvage radiaton therapy in patinents with prostate-specific antigen rise after radical prostatectomy Dr. Alberto Briganti Radical prostatectomy in men with oligometastatic Prostate Cancer Dr. José G. Pereira Lymphadenectomy after biochemical relapse after prostatectomy plus radiotherapy. Dr. Carlos Hernández High risk patients treated with radical prostatectomy and extended lymphadenectomy. Dr. Carlos Llorente 14:30h. Meeting Closing Remarks. Cocktail.
PARTICIPANTS Dr. Hashim U. Ahmed Professor and Chair of Urology, Imperial College London, England. Dr. Antonio Alcaraz Hospital Clínic IDIBAPS Univesitat de Barcelona. Dr. Ferrán Algaba Fundació Puigver, Barcelona. Universitat Autonoma de Barcelona. Dr. Pedro Arguis Clínica IMQ Zorrotzaurre, Bilbao. Dr. Ander Astobieta Dr. José María Banús Institut Catalá d Urología i Nefrología, Barcelona. Dr. Anders Bjartell. Skåne University Hospital, Malmö. Sweden. Dr. Alberto Briganti Vita Salute San Raffaele University, Milan. Dr. Xavier Cathelineau Institut Mutualiste Montsouris.Paris, France. Dr. Jean de la Rosette AMC University Hospital, Amsterdam. Dr. Mikel Gamarra Dr. Sangeet Ghai Princess Margaret Hospital, Toronto. Dr. Carlos Hernández Hospital General Univ. Gregorio Marañón, Madrid. Dr. Gaspar Ibarluzea Dr. Pilar Laguna AMC University Hospital, Amsterdam. Dr. Asier Leibar Hospital Universitario Infanta Sofía. Madrid. Dr. Carlos Llorente Hospital Univ. Fundación Alcorcón. Madrid. Dr. Jorge Mora Dr. José Gregorio Pereira Dr. José Rubio Instituto Valenciano de Oncología I.V.O. Valencia. Dr. Andrea Sánchez Dr. Miguel Sánchez Encinas Hospital Univ. Rey Juan Carlos. Madrid. Dr. Rafael Sánchez-Salas Institute Mutualiste Montsouris, París. Dr. Harriet Thoeny Inselspital Bern, University of Bern. Dr. Felipe Urdaneta Dr. Carla Valentí Ponsa Presidenta Territorial SEAP País Vasco. Hospital San Eloy, Barakaldo. Dr. Jochen Walz Institut Paoli-Calmettes Cancer Centre, Marseille/France.
THE PSA AND PROSTATE CANCER DILEMMA DATE February 23-24, 2017 VENUE Clínica IMQ Zorrotzaurre. Auditorium. Ballets Olaeta, 4. Bilbao. REGISTRATION FEE: 300 (+VAT) Registration fee includes: Documentation, admission to scientific events, coffee breaks and cocktails. Collaborators: Organizers: Supported by Technical Secretariat: Ballets Olaeta 4. 48014 Bilbao T. 94 439 35 10 - F. 94 427 03 20 www.urologiaclinicabilbao.com Gran Vía 81. 5º Dpto. 5. 48011. Bilbao T. 94 427 88 55 info@congresosxxi.com www.congresosxxi.com www.congresosxxi.com/reunioncancerdeprostata